Today: 7 February 2026
Subscribe
Browse Category

FDA Approvals News 7 December 2025 - 15 December 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025

December 15, 2025 — Eli Lilly and Company (NYSE: LLY) stock is starting the new week in focus as investors weigh a rapid-fire set of catalysts: a headline-grabbing Phase 3 result for next‑generation obesity drug retatrutide, fresh scrutiny around the FDA review timeline for oral GLP‑1 candidate orforglipron, ongoing capacity expansion in the U.S., and a notable analyst price-target tweak hitting the tape today. MarketBeat+3Reuters+3Reuters+3 Below is what’s moving Eli Lilly stock as of 15.12.2025, what the latest forecasts imply, and which risks matter most heading into 2026. Eli Lilly stock price today: where LLY is trading on Dec. 15,
15 December 2025
·····
Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ (etripamil) nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT)—a rapid heart rhythm disturbance that can be frightening, disruptive, and costly when it sends patients to emergency care. GlobeNewswire Yet in classic biotech fashion, the stock market’s reaction has been anything but simple. Despite the “yes” from regulators, MIST shares saw sharp volatility into the weekend, and investors
15 December 2025
·····
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Updated: December 14, 2025 Eli Lilly and Company (NYSE: LLY) heads into the new week with investors focused on one big theme: how far the company can extend its lead in obesity and cardiometabolic medicine while scaling supply and navigating pricing pressure. The stock’s most recent close (U.S. markets were shut Sunday) was $1,027.51. StockAnalysis Over the past two weeks, Lilly headlines have clustered around three catalysts that matter directly to the stock: Below is a detailed, publication-ready roundup of the key news, forecasts, and analyst takes driving Eli Lilly stock as of 14.12.2025. What’s moving Eli Lilly stock right
14 December 2025
·····
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage cardiovascular company. GlobeNewswire+1 The stock action was anything but calm. MIST closed at $2.41 on Dec. 12, down 18.31%, after swinging through a wide intraday range and printing exceptionally heavy volume. After-hours trading showed a modest rebound. StockAnalysis Below is a detailed breakdown of the latest Milestone Pharmaceuticals news, this week’s trading story, forecasts and analyst targets, and the week-ahead
14 December 2025
·····
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell: LLY finished the regular session at $1,027.51 (+1.80%) and traded in a tight range in the first part of the after-hours session, hovering near $1,028–$1,029. MarketWatch+2StockAnalysis+2 Note on timing: Saturday, Dec. 13, 2025 is a weekend, so U.S. stock markets
12 December 2025
·····
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

Published: 12 December 2025 GSK plc stock is back in focus on Friday as investors digest a fast-moving cluster of regulatory headlines across vaccines, infectious diseases and oncology—alongside ongoing buybacks and fresh consensus forecasts that map out how GSK’s revenue mix may evolve into 2031. On the New York Stock Exchange, GSK’s U.S.-listed ADR was trading around $48.88 in the latest available quote (prices move throughout the session). Below is a full, publication-ready roundup of the latest GSK stock news and market-moving developments available as of 12.12.2025, plus analyst forecasts and the key catalysts investors are watching into early 2026.
12 December 2025
······
Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

Pfizer (PFE) Stock Outlook After the November 21 FDA Win: Obesity Deals, Cost Cuts and a 6.7% Dividend Yield

As of December 11, 2025, Pfizer Inc. (NYSE: PFE) is trying to rewrite its post‑COVID story. The stock trades around $25.66 per share, after a choppy year of guidance upgrades, obesity-drug M&A, aggressive cost cuts and fresh regulatory wins in oncology and rare disease. Since November 21, 2025, a cluster of headlines — from an FDA approval in bladder cancer to a new GLP‑1 weight‑loss deal and expanding cost‑saving measures — has shifted how analysts and investors think about Pfizer’s earnings power going into 2026 and beyond. Pfizer stock today: price, yield and recent performance Pfizer’s board declared a $0.43
11 December 2025
·····
Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference (RNAi) platform, the company now has: The stock price has responded in full drama mode. As of the afternoon of December 11, 2025, Arrowhead shares are trading around $70, having touched intraday highs above $72 and notching a new 52‑week high in the low‑$70s. Investing.com+1 Over the last month, the stock has climbed from the low‑$40s to roughly $70 — a gain on the order of three‑quarters in just a few weeks. Investing.com At today’s levels, Arrowhead’s
11 December 2025
·····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys” list for 2026. Barchart.com+224/7 Wall St.+2 At the same time, the stock is still trading below its early‑October high, and investors are weighing Humira’s ongoing decline, softness in aesthetics, and regulatory risk against that growth story. Here’s a detailed look
11 December 2025
·····
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK plc (LSE: GSK; NYSE: GSK) is ending 2025 in full “pipeline flex” mode. On 10 December 2025 the company announced fresh US regulatory momentum for an experimental lung cancer drug and a new oncology collaboration, while the share price sits near multi‑year highs after a year of strong earnings and upgraded guidance.Stock Titan+1 Below is a deep dive into today’s news, how GSK shares are trading, what analysts are forecasting, and where the risk/reward balance looks to be heading into 2026. This is information, not personalised investment advice. GSK share price today: still near the top of its 2025
10 December 2025
······
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2 The rally caps a stunning year in which Arrowhead stock has delivered a year‑to‑date return of roughly 270% and a one‑year gain in the 160–200% range, depending on the data provider, vastly outpacing
8 December 2025
····
Medtronic PLC (MDT) Stock Outlook December 7, 2025: Price, Dividend, Hugo Robot FDA Win and 2026 Forecast

Medtronic PLC (MDT) Stock Outlook December 7, 2025: Price, Dividend, Hugo Robot FDA Win and 2026 Forecast

Updated: December 7, 2025 Key Takeaways 1. Medtronic (MDT) Stock Snapshot on December 7, 2025 As of the latest completed trading session (Dec. 5, 2025), Medtronic’s NYSE‑listed shares closed at $101.36, with modest after‑hours trading around $101.31. StockAnalysis Key stats at a glance: Trading over the last week has been choppy as markets digest macro headlines and rotations within healthcare. On Dec. 1, MDT fell about 1.9% to $103.34, underperforming the S&P 500 and Dow. A day later, it slipped another 1.3% to $102.03, leaving it around 4% below its recent 52‑week high of $106.33. MarketWatch+1 Even so, post‑earnings commentary
7 December 2025
····
1 … 3 4 5 6 7

Stock Market Today

BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Go toTop